Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

Similar documents
Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNP- AC/PC, Texas Children s Hospital, Pediatric Cardiology

Page 1. Disclosures. Background. No disclosures

Learning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?

Common dyslipidemia profiles in children

Young high risk patients the role of statins Dr. Mohamed Jeilan

Role of diet in prevention and treatment of hypercholesterolaemia/hypertriglyceridaemia in children C. Hartman (IL)

Blood Pressure Measurement (children> 3 yrs)

Disclosure. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Case Disclosure

Disclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values

Management of dyslipidaemia in HIV infected children: rationale for treatment algorithm

Atherosclerotic cardiovascular disease (CVD) is the number

How would you manage Ms. Gold

Familial hypercholesterolaemia in children and adolescents

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

Prevention of Heart Disease: The New Guidelines

Review of guidelines for management of dyslipidemia in diabetic patients

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Elements for a public summary

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

Harms of treatment with cholesterol-lowering drugs in. children: A systematic review of the published literature

Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report

Atherosclerotic cardiovascular disease remains the leading

To Screen or Not to Screen and Other Assorted Cholesterol Questions

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.

Latest Guidelines for Lipid Management

Disclosures. Obesity and Its Challenges: Outline. Outline 5/2/2013. Lan Vu, MD Division of Pediatric Surgery Department of Surgery

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

1/14/2013 Pediatric Cardiovascular Disease and the Future of our Children Linda Alwine FNP-BC Objectives Identify the prevalence and epidemiology of h

Understand obesity/overweight definition Understand medical consequences How to better evaluate and manage obese/overweight pediatric patients

Current Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

EuroPRevent Risk assessment models: what is to come? Risk Assessment Models: Applications in Clinical Practice

LIPID CLUB Rome, 2014

ATP IV: Predicting Guideline Updates

Lipoprotein Particle Profile

PREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION

METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

STATIN UTILIZATION MANAGEMENT CRITERIA

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Statistical Fact Sheet Populations

2017Adult Male Preventive Health Guidelines

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

The Institute of Medicine January 8, 2009

Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center

Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice

1. Which one of the following patients does not need to be screened for hyperlipidemia:

Lipids Testing

No relevant financial relationships

Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.

Macrovascular Management. What s next beyond standard treatment?

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

MOLINA HEALTHCARE OF CALIFORNIA

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

DYSLIPIDEMIA RECOMMENDATIONS

EUROPEAN SOCIETY OF CARDIOLOGY- CONGRESS 2010

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Comparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, : Review

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Contemporary management of Dyslipidemia

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

SCHEDULE OF BENEFITS PLAN C

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Treating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC

NEW GUIDELINES FOR CHOLESTEROL

Advances in Lipid Management

LIPID GUIDELINES: 2015

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Drug therapy of high-risk lipid abnormalities, particularly

Obesity Prevention and Treatment Program Primer

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD

Tusculum College. Benefit Summary. $25 Copay. $25 Copay. after Deductible. 20% after Deductible 20% after Deductible

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

Established Risk Factors for Coronary Heart Disease (CHD)

Prevention and Management Of Obesity Adolescents & Children

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Michigan Department of Health and Human Services Preventive Services Coverage Guidelines Healthy Michigan Plan

Lipid Management 2013 Statin Benefit Groups

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.

Early and Periodic Screening, Diagnosis and Treatment (EPSDT)

Pharmacy Management Drug Policy

PCSK9 Inhibition: From Genetics to Patients

New Cholesterol Guidelines What the LDL are we supposed to do now?!

40% minimum reduction from

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

Transcription:

Is Universal Pediatric Lipid Screening Justified? YES Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

None Disclosures

What is a Pediatrician? Pediatrics is the specialty of medical science concerned with the physical, mental and social health of children from birth to young adulthood. Pediatricians encompasses a broad spectrum of health services ranging from preventative health care to the diagnosis and treatment of acute and chronic diseases.

General Pediatrics Screening Screening healthy population Selective screening UNIVERSAL SCREENING Newborn screen Hgb/HCT Lead levels MCAT questionaire HEADSS questionaire Hearing Vision

Prevention Strategies 1. Primordial Prevention > Prevent the development of RISK FACTORS 2. Primary Prevention > Prevent the Disease 3. Secondary Prevention > Early disease state & prevent symptomatic manifestation 4. Tertiary Prevention > Attempt to minimize the adverse impact of the disease

Prevalence of Common Pediatric Diseases Disease Inheritance Prevalence PKU AR 1/14,000 1/20,000 Galactosemia AR 1/60,000 CAH AR 1/15,000 1/20,000 Congenital Hypothyroid Multifactorial 1/3000 CF AR 1/3500 Heterozygous FH AR 1/500

Evolution of Pediatric Lipid Guidelines National Cholesterol Education Program (NCEP), Report of the Expert Panel on Blood Cholesterol Levels in Children & Adolescents, 1992 AAP-Cholesterol in Children (Committee on Nutrition), 1998 Lipid Screening & Cardiovascular Health in Children, 2008 Lipid Research Clinic Prevalence Study 1971 NCEP 1988 NCEP 1992 AAP 1998 USPSTF 2007 AAP 2008 NLA 2011 NHLBI 2011 AAP Bright Future 2012 USPSTF 2016 1971 1990 2000 2005 2010 2015 2016

40 to 60% of children would be missed with dyslipidemia

Morbid Obesity Rates Increased

USPSTF Lipid Screening Recommendations Children ages 1-20 concludes that there is (I)nsufficient evidence to recommend routine screening (2016) Did not recommend: BMI screening obesity (USPSTF, 2005)

Universal Lipid Screening 9 to 11 years of age

Screening Test Non-Fasting: Non-HDLc (TC-HDL) Sensitivity (88-96%) Specificity (98%) Fasting: Lipid Panel TC, LDL, TG, HDL VLDL TG/HDL (Obesity)

Pediatric Lipid Studies Korean Autopsy Study Lipid Research Prevalence Study PDAY Study Bogalusa Heart Study Muscatine Study CV Risk-Young Finns Study CARDIA Study NHANEs Statin Medication Studies DISC Study: The Dietary Intervention Study in Children STRIP Study: CATCH Study

Atherosclerosis Begins in Childhood

Dietary counseling beginning in infancy is effective with results sustained into young adult life Sustained lower LDL-C, Lower SBP/DBP, less obesity and less insulin resistance

Lipid Risk Stratification Risk Factors Moderate Risk High Risk Family History - Premature CVD or Dyslipidemia BMI/Obesity >95 th percentile >97% percentile Hypertension No Rx Medications HDL-C <40mg/dl - Tobacco Use - Current Smoker Risk Conditions -Kawasaki with regressed coronary aneurysm -Kawasaki with current coronary aneurysm -Chronic Inflammatory Dz (SLE, JRA) -HIV Infection -Nephrotic Syndrome -Type I or II Diabetes -Heart Transplant -Chronic Kidney Dz/ESRD or post renal transplant

When to Consider Treatment 1. Failure 6-12 months of lifestyle management 2. Age > 10 years of age 3. LDL-C Level: LDL-C (130-160mg/dL): 2 high level risk factors or conditions 1 high + 2 moderate risk factor or conditions LDL-C (160-189mg/dL): Positive Family History 1 high risk factor/condition 2 moderate risk factors/conditions LDL-C (>190mg/dL) No additional factors required

Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized Controlled Trial No difference in academic performance, hormones, safety, labs JAMA. 2004;292(3):331-337.

Statin Medications are Safe in Pediatrics Well tolerated FDA approved > 10 years of age Side-effects rare Teratogenic

Conclusions Pediatricians should practice primoridal prevention Atherosclerosis begins in childhood Screening can be performed early and affect the natural course of the disease Epidemic obesity & increasing rates of morbid obesity Lipid screening can be performed Fasting or Non-fasting Effective interventions Implementation NHLBI screening guidelines are lagging Pediatricians continue to be the experts in preventative screening

THANK YOU!

Provider Responses

Provider Responses

Provider Response

Principles for Screening Test 1. Condition should be an important health problem 2. Should be detectable in the early stages 3. Early detection & treatment can affect the course of the disease 4. Should be an acceptable treatment 5. The test should have a high sensitivity and positive predictive value (validity & reliability) 6. The cost of screening should be economically balanced